Kevin Kovach, MD
Ophthalmology · Elmhurst, ILNPI 1386643658
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,003 of the $33,718 with a category attached, or 62.3%. 46 manufacturers reported payments, led by Glaukos Corporation at 29.0% of the total. 2025 is the largest year on record at $10,038, 2.3 times the $4,449 reported in 2019. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 722 payments — averaging $46.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$10K
- Carl Zeiss Meditec USA, Inc.$5K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$2K
- Alcon$2K
- Aerie Pharmaceuticals, Inc.$2K
- plus $11K from 40 others
Across 9 payments — averaging $5642.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$51K
What the payments were for
- Speaking & faculty fees$5,33816%
- Grants$1,5004%
- Food & beverage$21,00362%
- Education$1,5004%
- Gifts$1450%
- Other$4,23213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$5,574
- LUMERA 700$3,435
- iStent inject Trabecular Micro-Bypass Stent System$1,631
- iStent Trabecular Micro-Bypass Stent System$1,500
- IOLMaster 700$797
- XEN GLAUCOMA TREATMENT SYSTEM$498
- Tecnis Simplicity$444
- Tecnis IOL$425
- IACCESS$382
- Hydrus Microstent$380
- iDose$342
- Photrexa Viscous and Photrexa$342
- iStent inject W$267
- RAYNER CATARACT SET 1$252
- RayOne EMV$252
- RayOne Spheric$252
- RayOne Aspheric$252
- Kahook Dual Blade$250
- Clearpath$250
- Ahmed Glaucoma Valve$250
How this compares
$33,718 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 128 | $88,549 |
| RhopressaNetarsudil Mesylate | 93 | $65,164 |
| LumiganBimatoprost | 94 | $63,490 |
| XiidraLifitegrast | 34 | $54,373 |
| Prednisolone Acetate | 1,012 | $43,301 |
| VevyeCyclosporine | 53 | $41,191 |
| XdemvyLotilaner | 16 | $30,772 |
| RestasisCyclosporine | 33 | $29,409 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $23,444 |
| EysuvisLoteprednol Etabonate | 41 | $20,802 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 79 | $17,375 |
| Timolol Maleate | 365 | $14,821 |
| ProlensaBromfenac Sodium | 39 | $14,055 |
| MoxifloxacinMoxifloxacin Hcl | 719 | $13,502 |
| Alphagan PBrimonidine Tartrate | 24 | $10,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $1,677 | $153,713221 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,312 | $126,883207 claims |
| Bausch & Lomb Americas Inc.Xiidra | $1,021 | $54,37334 claims |
| Harrow Eye, LLCVevye | $468 | $41,19153 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $221 | $30,77216 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax | $530 | $28,481120 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $535 | $20,80241 claims |
| Thea Pharma Inc.Iyuzeh | $101 | $8,06314 claims |
| AlconSimbrinza | $2,034 | $8,00432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Elmhurst
- Mateen AliniazeeElmhurst$122K
- Donald SandersElmhurst$62K
- Marius GradianuElmhurst$42K
- Saad AhmadElmhurst$37K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.